インディアナ州における慢性リンパ性白血病の臨床試験
インディアナ州内の拠点で、慢性リンパ性白血病に関する12件の研究が参加者を募集しています。
インディアナ州内の都市
公式研究テキスト（英語）
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Reid Health, Richmond
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 101, Fort Wayne
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07582432Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- UChicago Medicine Northwest Indiana, Crown Point
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT04269902A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06697184A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Fort Wayne Medical Oncology and Hematology ( Site 5444), Fort Wayne
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Parkview Research Center at Parkview Regional Medical Center ( Site 0002), Fort Wayne
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06136559Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Indiana University Health Arnett, Inc., Lafayette
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Fort Wayne Oncology and Hematology, Fort Wayne
- Hematology Oncology of Indiana, Indianapolis
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07221500Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
- Hematology Oncology of Indiana, Indianapolis
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/31更新 · NCT07516093A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Northwest Cancer Center - Dyer Clinic /ID# 268478, Dyer
被験者募集中第3相
18歳以上 · 全性別 · 2026/04/09更新 · NCT06428019AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- American Oncology Partners, Fort Wayne
被験者募集中第1相
18歳以上 · 全性別 · 2025/12/10更新 · NCT05602363Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- Goshen Center for Cancer Care, Goshen
被験者募集中第1/2相
18歳以上 · 全性別 · 2022/08/04更新 · NCT04502394ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。